09:40 AM EDT, 07/02/2024 (MT Newswires) -- Inozyme Pharma ( INZY ) said Tuesday that the US Food and Drug Administration has awarded Fast Track designation to INZ-701 to treat ABCC6 deficiency, a disease caused by gene mutations.

The designation is intended to accelerate the development and review of treatments for severe or life-threatening conditions that show the potential to address unmet needs, the company said.

Inozyme said it expects to finalize study plans for pediatric patients by the end of this year.

Price: 4.47, Change: +0.06, Percent Change: +1.36